BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Jan 11, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

PEG-SN38: Phase II started

Enzon began an open-label, U.S. Phase II trial evaluating 9 mg/kg intravenous PEG-SN38 given once weekly for 3 weeks of...

Read the full 79 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >